




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 403/14, A61K 31/40</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/47518 (43) International Publication Date: 23 September 1999 (23.09.99)</p>
<p>(21) International Application Number: PCT/EP99/01534 (22) International Filing Date: 10 March 1999 (10.03.99) (30) Priority Data: 60/078,331 17 March 1998 (17.03.98) US (71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH]; 124 Grenzacherstrasse, CH-4070 Basel (CH). (72) Inventors: DHINGRA, Urvashi, Hooda; 82 Beech Street, Nutley, NJ 07110 (US). HURYN, Donna, Mary; 8 Tyler Court, Allentown, NJ 08501 (US). KE, June; 5 Carlton Drive, Montclair, NJ 07043 (US). WEBER, Giuseppe, Federico; 192 Anderson Parkway, Cedar Grove, NJ 07009 (US). (74) Agent: MEZGER, Wolfgang; 124 Grenzacherstrasse, CH-4070 Basel (CH).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: SUBSTITUTED BISINDOLYMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION</p> <div style="text-align: center;">  <p>(I)</p> </div> <p>(57) Abstract</p> <p>Substituted pyrroles of formula (I) wherein R¹ is hydrogen and R² is methyl or R¹ is methyl and R² is hydrogen or R¹ is hydroxymethyl and R² is methyl as well as pharmaceutically acceptable prodrugs or pharmaceutically acceptable salts thereof are antiproliferative agents useful in the treatment of cancer.</p>		

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

SUBSTITUTED BISINDOLYMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION

The invention relates to substituted pyrroles of formula



10

wherein R^1 is hydrogen and R^2 is methyl or
 R^1 is methyl and R^2 is hydrogen or
 R^1 is hydroxymethyl and R^2 is methyl

as well as to pharmaceutically acceptable prodrugs or pharmaceutically acceptable salts thereof.

15




The compounds of formula I have antiproliferative activity, specifically, they inhibit cell division in G2/M phase of the cell cycle and are generally referred to as "G2/M phase cell-cycle" inhibitors.

20

The compounds of formula I are covered by formula I of U.S.P. 5,057,614 without being specifically disclosed as a group or individually. In addition, the above-mentioned activity of the

compounds of the present invention has nowhere been disclosed or made obvious in U.S.P. 5,057,614 and, therefore, is surprising.

Formula I above comprises the following three compounds:



The term "pharmaceutically acceptable prodrugs" means a compound that may be converted under physiological conditions or by solvolysis to any of the compounds of formula I or to a pharmaceutically acceptable salt of said compounds.


5 The compounds of formula I, as well as pharmaceutically acceptable salts of said compounds, are prepared by reactions represented in the following Schemes. The synthesis of each of these compounds is also described in Examples 1-3.

10 Compound I-1 can be prepared by reacting (1-methyl-6-nitro-1H-indol-3-yl)-oxo-acetyl chloride (3) with [1-(2,2-dimethyl-propionyl)-1H-indol-3-yl]-3-ethanimidic acid 1-methylethylester hydrochloride (7) and treating the reaction product with a base.


15 Compound I-2 can be prepared by reacting (1-methyl-1H-indol-3-yl)-oxo-acetyl chloride (17) with [1-(2,2-dimethyl-propionyl)-6-nitro-1H-indol-3-yl]-3-ethanimidic acid 1-methylethylester hydrochloride (19) and treating the reaction product with a base.

20 Compound I-3 can be prepared by reacting (1-methoxymethyl-1H-indol-3-yl)-oxo acetyl chloride (10) with (1-methyl-6-nitro-1H-indol-3-yl)-3-ethanimidic acid 1-methylethylester hydrochloride (15) and treating the reaction product with an acid.


SCHEME 1



SCHEME 2



SCHEME 3



The antiproliferative activity of the compounds of the invention is demonstrated below. These effects indicate that the compounds are useful in treating cancer, in particular solid tumors.

The estrogen receptor negative epithelial breast carcinoma line (MDA-MB-435) was
5 purchased from American Type Cell Culture Collection (ATCC; Rockville, MD) and was grown
in the medium recommended by ATCC. For analysis of the effect of the test compounds on
growth of these cells, the cells were plated at 2000 cells per well in a 96-well tissue culture plate
("test plate"), and were incubated overnight at 37°C with 5% CO₂. The next day, the test
compounds were dissolved in 100% dimethyl sulfoxide (DMSO) to yield a 10 mM stock
10 solution. Each compound was diluted with sterile distilled water to 1 mM and then was added to
triplicate wells of a 96-well "master plate" containing medium in a sufficient quantity to yield a
final concentration of 40 µM. The compounds were serially diluted in medium in the "master
plate." One-fourth final volume of the diluted compounds was transferred to duplicate "test
plates." DMSO was added to a row of "control cells" such that the final concentration of
15 DMSO in each well was 0.1%. The "test plates" were returned to the incubator and 3 days post
addition of test compound one "test plate" was analyzed as described below. Similarly, 5 days
after addition of test compound, the second "test plate" also was analyzed as described below.

3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (thiazolyl blue;
20 MTT) was added to each well to yield a final concentration of 1 mg/ml. The plate was then
incubated at 37°C for 3 hours. The MTT-containing medium was then removed and 50 µl 100%
ethanol was added to each well to dissolve the resulting formazan metabolite. To ensure
complete dissolution, plates were shaken for 15 minutes at room temperature. Absorbencies
were read in a microtiter plate reader (Molecular Dynamics) at a wavelength of 570 nm with a
25 650 nm reference. Percent inhibition was calculated by subtracting the blank from all wells, then
subtracting the division of the average absorbance of each test triplicate by the average of the
controls from 1.00. Inhibitory concentrations (IC₅₀ and IC₉₀) were determined from the linear
regression of a plot of the logarithm of the concentration versus the percent inhibition.

The colon adenocarcinoma line SW480 and the colon carcinoma line HCT-116 also were obtained from the ATCC and were tested according to the same protocol provided above with the following modifications. Cell line SW480 was plated at 1000 cells per well and analyzed at 6 days post addition of the test compound. Cell line HCT-116 was plated at 750 cells per well and analyzed at 4 days post addition of test compound. For the MTT analysis, plates were centrifuged at 1000 rpm for 5 minutes prior to aspiration of the MTT-containing medium, and 100 μ l 100% ethanol was used to dissolve the formazan.

The results of the foregoing *in vitro* tests are set forth below in Tables I-III.

TABLE I

Antiproliferative Activity In Cell Line MDA-MB-435

<u>Compound</u>	<u>IC₅₀ (μM)</u>
Compound I-1	0.03*
Compound I-3	0.05*
Compound I-2	0.6*

* An average of at least three separate experiments.

TABLE II

Antiproliferative Activity In Cell Line HCT-116

<u>Compound</u>	<u>IC₅₀ (μM)</u>
Compound I-1	0.17*
Compound I-3	0.23*
Compound I-2	1.66*

* An average of at least three separate experiments.

TABLE III**Antiproliferative Activity In Cell Line SW480**

<u>Compound</u>	<u>IC₅₀ (μM)</u>
Compound I-1	0.20*
Compound I-3	0.22*
Compound I-2	1.86*

* An average of at least three separate experiments.

5
10
15
For analysis of the effect of the compounds on cell cycle progression, MDA-MB-435 cells (ATCC; Rockville, MD) were plated at 1×10^6 cells/10 mls per 10 cm dish in the following growth medium: RPMI 1640 + 10% Heat-Inactivated Fetal Bovine Serum, 2 mM L-glutamine and 50 U/ml pen-strep (all from GIBCO/BRL, Gaithersburg, MD). The cells were incubated overnight at 37° C with 5% CO₂. The next day, 10 μl of each of the compounds to be tested, in a 100% DMSO solution, was added to individual dishes to obtain 1/1000x final concentration of the stock solution. In addition, 10 μl 100% DMSO was added to a control dish. The final concentration of DMSO in all plates, including the control, was 0.1%. The plates were returned to the incubator.

20
25
Thereafter, at various periods of time, the medium in each plate was removed to a 50 ml centrifuge tube. The cell layer remaining in the dish was then washed with 5 ml of phosphate buffered saline (PBS; GIBCO/BRL). The PBS was removed and combined with the medium in the appropriate tube. The cells were trypsinized for 5 minutes at 37° C, and the solution was collected and combined with the medium and PBS in the appropriate tubes. The tubes were then centrifuged for 5 minutes at 1200 rpm. The cells were fixed by removing the supernatant, tapping the tube to distribute the pellet, then adding 5 mls of cold 70% ethanol while vortexing gently. The cells were then stored at -20° C for >24 hours.

The cell-containing tubes were taken out of freezer and allowed to sit at room temperature for 20-30 minutes. The tubes were centrifuged at 3000 rpm for 5 minutes. The supernatant was removed, the pellets were washed with 5 ml PBS, and the tubes were centrifuged as above. Subsequently, the supernatant was removed, and the pellet was resuspended in 0.5 ml PBS. Thereafter, 0.5 ml RNase A (1 mg/ml in PBS) was added to each tube, and the tubes were incubated at 37° C for 15 minutes. 100 µl propidium iodide (Sigma, St. Louis, MO) (1 mg/ml in PBS) was added to each tube, and the tubes were then incubated at room temperature for 2-3 minutes. Each resulting solution was passed through a filter cap tube (Becton Dickinson, San Jose, CA, #2235).

Samples were read in a FACSort machine (Becton-Dickinson) using the manufacturer's CellQUEST program, and analyzed with the manufacturer's ModFIT software. This measurement provides an indication of the percent of cells in each of the following phases: G0/G1, DNA synthesis (S) and G2/M phases.

The results of a cell cycle progression experiment analyzed at day 1 post addition of test compounds I-1, I-2 and I-3 are summarized below in Table IV.

TABLE IV

Effect Of Test Compounds On Cell Cycle

<u>Compound</u>	<u>Concentration</u>	<u>% Of Cells In Each Cell Cycle Phase</u>		
		<u>G1</u>	<u>S</u>	<u>G2/M</u>
DMSO	0.1 %	43.93 %	41.08 %	14.99 %
Compound I	0.1 μ M	8.27 %	25.21 %	66.52 %
Compound I	0.03 μ M	45.30 %	34.67 %	20.03 %
Compound I	0.01 μ M	44.95 %	41.04 %	14.00 %
Compound I-3	0.3 μ M	1.11 %	24.99 %	73.90 %
Compound I-3	0.1 μ M	15.54 %	24.06 %	60.40 %
Compound I-3	0.03 μ M	45.45 %	38.06 %	16.50 %
Compound I-2	10 μ M	10.41 %	35.25 %	54.34 %
Compound I-2	3 μ M	3.26 %	48.75 %	47.99 %
Compound I-2	1 μ M	27.21 %	30.19 %	42.60 %

10 The results summarized in Tables I-IV above demonstrate that compounds I-1, I-2 and I-3 have antiproliferative activity; specifically, they cause an accumulation of cells in the G2/m phase of the cell cycle.

15 The pyrroles of formula I above and their aforementioned salts can be used as medicaments, for example, in the form of pharmaceutical preparations, which can be administered orally, for example, in the form of tablets, coated tablets, dragees, hard or soft gelatin capsules, solutions, emulsions or suspensions. They can also be administered rectally, for example, in the form of suppositories or parenterally, for example, in the form of injection solutions.

For the manufacture of pharmaceutical preparations these compounds can be formulated with therapeutically inert, inorganic or organic carriers. Lactose, maize starch or derivatives thereof, talc, steric acid or its salts can be used as such carriers for tablets, coated tablets, dragees and hard gelatin capsules. Suitable carriers for soft gelatin capsules are vegetable oils, waxes, fats, semi-solid or liquid polyols. Depending on the nature of the active substance no carriers are, however, generally required in the case of soft gelatin capsules. Suitable carriers for the manufacture of solutions and syrups are, water, polyols, saccharose, invert sugar and glucose. Suitable carriers for injection are water, alcohols, polyols, glycerine, vegetable oils, phospholipids and surfactants, suitable carriers for suppositories are natural or hardened oils, waxes, fats and semi-liquid polyols.

The pharmaceutical preparations can also contain preserving agents, solubilizing agents, stabilizing agents, wetting agents, emulsifying agents, sweetening agents, coloring agents, flavoring agents, salts for varying the osmotic pressure, buffers, coating agents or antioxidants. They can also contain still other therapeutically valuable substances.

As mentioned above, the pyrroles of formula I and their aforementioned salts can be used in the treatment or control of oncological disorders. The dosage can vary within wide limits and will, of course, be adjusted to the individual requirements in each particular case. In general, in the case of oral or parenteral administration to adult humans weighing about 70 kg, a daily dosage of about 10 mg to about 10,000 mg, preferably from about 200 mg to about 5,000 mg, more preferably to about 1000 mg, should be appropriate, although the upper limit may be exceeded when indicated. The daily dosage can be administered as a single dose or in divided doses, or for parenteral administration, it may be given as continuous infusion.

The following Examples illustrate the present invention.

EXAMPLE 1

5 Preparation of 3-(1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (I-1)

A. 1-Methyl-6-nitro-1H-indole (2)

To a slurry of 0.33 g (8.3 mmol) of NaH (60% dispersion in oil) in 30 ml of dried dimethylformamide ("DMF"), was added 0.973 g (6.00 mmol) of commercially available
10 6-nitro-1H-indole (1) at 0-5°C over a period of 10 minutes. After 1 hour stirring at the same temperature, 0.75 ml (12.1 mmol) of methyl iodide was added and the mixture was stirred at the same temperature for 30 minutes, then at room temperature for 1 hour, poured into ice and water and extracted with ethyl acetate. The organic phase was washed with brine, dried over MgSO₄, and concentrated to yield 0.814 g (77.5%) of 1-methyl-6-nitro-1H-indole (2) as a yellow solid.
15 This material was used without purification.

B. (1-Methyl-6-nitro-1H-indol-3-yl)-oxo-acetyl chloride (3)

To a solution of 1.33 g (7.55 mmol) of 1-methyl-6-nitro-1H-indole (2) in 40 ml of ether were added 1.5 ml (17.2 mmol) of oxalyl chloride at 0-5°C under Argon. A precipitate was formed.
20 After 3 hours stirring, the resulting solid was filtered, washed with a small amount of ether and dried to yield 1.9 g (95%) of (1-methyl-6-nitro-1H-indol-3-yl)-oxo-acetyl chloride (3) as a yellow solid. This material was used without purification.

C. [1-(2,2-Dimethyl-propionyl)-1H-indol-3-yl]-acetonitrile (6)

25 Using the procedure of subpart A above, the N-alkylation reaction of 10.2 g (65 mmol) of commercially available (1H-indol-3-yl)-acetonitrile (5) with 8.7 ml (71 mmol) of trimethylacetyl chloride and 3.4 g (85 mmol) of NaH (60% dispersion in oil) as a base in 115 ml of DMF yielded 6.6 g (38.7%) of [1-(2,2-dimethyl-propionyl)-1H-indol-3-yl]-acetonitrile (6) as a yellow oil after chromatographic purification.

D. [1-(2,2-Dimethyl-propionyl)-1H-indol-3-yl]-3-ethanimidic acid 1-methylethylester hydrochloride (7)

To a slurry of 6.6 g (27.5 mmol) of [1-(2,2-dimethyl-propionyl)-1H-indol-3-yl]-acetonitrile (6) from Step C above in 105 ml of 2-propanol, 40 ml (0.563 mol) of acetyl chloride was added dropwise at 0-5°C over a 20 minute period. The reaction mixture was stirred at room temperature overnight, concentrated and the residue was diluted with approximately 75 ml of ethyl acetate, heated for 15 minutes on a steam bath, cooled and placed in a freezer. The precipitate was filtered and dried to yield 6.0 g (65.0%) of [1-(2,2-dimethyl-propionyl)-1H-indol-3-yl]-3-ethanimidic acid 1-methylethylester hydrochloride (7) as a white solid.

E. 3-[1-(2,2-Dimethyl-propionyl)-1H-indol-3-yl]-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (4)

To a solution of 1.25 g (4.69 mmol) of (1-methyl-6-nitro-1H-indol-3-yl)-oxo-acetyl chloride (3) from Step B above and 1.6 g (4.75 mmol) of [1-(2,2-dimethyl-propionyl)-1H-indol-3-yl]-3-ethanimidic acid 1-methyl ethylester hydrochloride (7) from Step D above in 80 ml of methylene chloride was added 2.6 ml (18.65 mmol) of triethylamine at 0°C and under Argon. After stirring at the same temperature for 30 minutes, the reaction mixture was then stirred at room temperature for 3 1/2 hours and diluted with more methylene chloride. The organic phase was washed with water, 0.5N HCl solution, brine, dried over MgSO₄ and concentrated to give 3.01 g of a foam. This material was dissolved in 50 ml of toluene and treated with 987.9 mg (5.19 mmol) of p-toluenesulfonic acid at 0°C. After 3 hours stirring at room temperature the reaction mixture was extracted with methylene chloride. The organic phase was washed with a saturated NaHCO₃ solution, brine, dried over MgSO₄ and concentrated to give 3.9 g of crude material. Chromatographic purification on a silica gel column, yielded 1.7 g (77.%) of 3-[1-(2,2-dimethyl-propionyl)-1H-indol-3-yl]-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (4) as an orange solid. mp >146°C with dec. MS: (M⁺), m/z 470.

F. 3-(1H-Indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (I-1)

1.7 g (3.61 mmol) of 3-[1-(2,2-dimethyl-propionyl)-1H-indol-3-yl]-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (4) from Step E above in 60 ml of methanol was treated with 5.6 ml (8.96 mmol) of a 1.6 molar solution of NaOCH₃ in methanol. The reaction was stirred at room temperature for 1 hour, poured in 2N-HCl/ice and extracted with ethyl acetate. The organic extracts were dried on anhydrous MgSO₄ and concentrated to yield, after chromatographic purification, 394.7 mg (28%) of 3-(1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (I-1) as a red solid mp >280°C. MS: (M⁺), m/z 386.

10

EXAMPLE 2Preparation of 3-(1-hydroxymethyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (I-3)15 A. 1-Methoxymethyl-1H-indole (9)

Using the procedure of Example 1, Step A, the N-alkylation reaction of 1.17 g (10 mmol) of commercially available indole (8) with 1 ml (13.1 mmol) of chloromethyl methyl ether and 0.48 g (12 mmol) of NaH (60% dispersion in oil) as a base in 22 ml of DMF yielded 1.4 g (86.9%) of 1-methoxymethyl-1H-indole (9) as a colorless oil, after chromatographic purification.

20

B. (1-Methoxymethyl-1H-indol-3-yl)-oxo-acetyl chloride (10)

Using the procedure of Example 1, step B, the reaction of 0.23 g (1.43 mmol) of 1-methoxymethyl-1H-indole (9) from Step A above with 0.25 ml (2.86 mmol) of oxalyl chloride in 3.5 ml of ether produced 0.174 g (48.5%) of (1-methoxymethyl-1H-indol-3-yl)-oxo-acetyl chloride (10) as a yellow solid. This material was used without purification.

25

C. (6-Nitro-1H-indol-3-yl)-acetonitrile (13)

To a stirred solution of 44.27 g (0.204 mol) of 6-nitrogramine (12) [Jackson B. Hester *J. Org. Chem.*, 29: 1158 (1964)] in 450 ml of acetonitrile 44.59 g (0.31 mol) of methyl iodide was added at 0-5°C over a period of an hour. The reaction mixture was stirred at room temperature for three hours, then a solution of 26.6 g (0.543 mol) of sodium cyanide in 225 ml of water added at once. The reaction mixture was heated at 32°C overnight, cooled to room temperature and the product extracted 3 times with a total of 800 ml of ethyl acetate and 300 ml of water. The combined extracts were washed with water, 1N HCl solution, a saturated sodium bicarbonate solution, dried on MgSO₄ and the solvent evaporated in vacuo. The orange-brown residue (41.3 g) was dissolved in 200 ml of warm ethyl acetate and passed through a small pad of silica gel to produce 28.9 g (70.4%) of (6-nitro-1H-indolyl-3-yl)-acetonitrile (13) as a yellow solid after evaporation of the solvent.

D. (1-Methyl-6-nitro-1H-indol-3-yl)-acetonitrile (14)

65.5 g (0.474 mol) of powdered potassium carbonate was added to a solution of 28.9 g (0.143 mol) of (6-nitro-1H-indol-3-yl)-acetonitrile (13) from Step C above in 230 ml of dimethylformamide at room temperature. The suspension was stirred for 40 minutes then 25.48 g (0.179 mol) of methyl iodide was added dropwise over 65 minutes. After stirring at room temperature over night the reaction mixture was cooled and poured into a total of 600 ml of water. The precipitate was filtered, washed with a little water and dried on phosphor anhydride until reaching constant weight. The procedure yielded 30.4 g (95.4%) of (1-methyl-6-nitro-1H-indol-3-yl)-acetonitrile (14), which was used without further purification.

E. (1-Methyl-6-nitro-1H-indol-3-yl)-3-ethanimidic acid 1-methylethylester hydrochloride (15)

A stream of HCl gas was bubbled into a stirred suspension of 82 g (0.382 mol) of (1-methyl-6-nitro-1H-indol-3-yl)-acetonitrile (14) from Step D above, in 1000 ml of 2-propanol at 0-10°C. After adding approximately 350 g of HCl, ether was added to the reaction mixture until a precipitate was formed. The solid was collected, washing with ether and dried in vacuo to yield

102 g (85.7%) of (1-methyl-6-nitro-1H-indol-3-yl)-3-ethanimidic acid 1-methylethylester hydrochloride (15).

F. 3-(1-Methoxymethyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (11)

Using the procedure of Example 1, Step E, the condensation reaction of 1.3 g (5.17 mmol) of oxoacetyl chloride (10) from Step B above, with 1.7 g (5.45 mmol) of (1-methyl-6-nitro-1H-indole)-3-ethanimidic acid 1-methyl ethylester hydrochloride (15) from Step E above in 95 ml of methylene chloride, yielded 1.08 g (48.5%) of 3-(1-methoxymethyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (11) as an orange solid, mp >250°C with dec. MS: (M⁺), m/z 430.

G. 3-(1-Hydroxymethyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (I-3)

A solution of 727.5 mg of 3-[1-(methoxymethyl)-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (11) from Step F above in 65 ml of THF was treated with approximately 40 ml of 2N HCl. The reaction mixture was refluxed for 5 hours, cooled and the product was extracted with ethyl acetate. The organic phase was dried on MgSO₄ and the solvent evaporated to give an orange solid. Chromatographic purification of this material yielded 123.3 mg of 3-(1-hydroxymethyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (I-3) as a red solid, mp 210-213°C. MS: (M⁺), m/z 416.

EXAMPLE 3

Preparation of 3-(1-Methyl-1H-indol-3-yl)-4-(6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (I-2)

A. (1-Methyl-1H-indol-3-yl)-oxo-acetyl chloride (17)

- 5 Using the procedure of Example 1, Step B, the reaction of 6 ml (47 mmol) of commercially available 1-methyl-1H-indole (16) with 8 ml (92 mmol) of oxalyl chloride in 120 ml of ether, produced 7.6 g (73.2%) of (1-methyl-1H-indol-3-yl)-oxo-acetyl chloride (17) as a yellow solid. This material was used without purification.

10

B. [1-(2,2-Dimethyl-propionyl)-6-nitro-1H-indol-3-yl]-acetonitrile (18)

- Using the procedure of Example 1, Step A, the N-alkylation reaction of 346.6 mg (1.72 mmol) of 6-nitro-1H-indol-3-yl-acetonitrile (13) from Example 2, Step C with 0.3 ml (2.44 mmol) of trimethylacetyl chloride and 70.8 mg (1.77 mmol) of NaH (60% dispersion in oil) as a base in 15 ml of DMF yielded after chromatographic purification, 287.7 mg (43.2%) of [1-(2,2-dimethyl-propionyl)-6-nitro-1H-indol-3-yl]-acetonitrile (18) as a yellow oil.

C. [1-(2,2-Dimethyl-propionyl)-6-nitro-1H-indol-3-yl]-3-ethanimidic acid 1-methylethyl-ester hydrochloride (19)

- 20 A stream of HCl gas was bubbled for 3 minutes into a constantly stirred suspension of 1.45 g (5.08 mmol) of [1-(2,2-dimethyl-propionyl)-6-nitro-1H-indol-3-yl]-3-acetonitrile (18) from Step B above in 90 ml of 2-propanol at 0-5°C. The reaction mixture was stirred at room temperature for 21 hours. The solvent was evaporated in vacuo to give 1.95 g (100%) of a yellow solid (19). This material was used without further purification.

25

D. 3-[1-(2,2-Dimethyl-propionyl)-6-nitro-1H-indol-3-yl]-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione (20)

Using the procedure of Example 1, Step E, 1.1 g (4.96 mmol) of oxoacetyl chloride (17) from Step A above was reacted with 1.95 g (5.08 mmol) of [1-(2,2-dimethyl-propionyl)-6-nitro-1H-indol-3-yl]-3-ethanimidic acid 1- methylethylester hydrochloride (19) from Step C above and 2.1 ml (17.94 mmol) of triethylamine in 120 ml of methylene chloride, the resulting product was treated with 1.1 g (5.78 mmol) of p-toluenesulfonic acid monohydrate in 80 ml of toluene, yielding 1.3 g (62.1%) of 3-[1-(2,2-dimethyl-propionyl)-6-nitro-1H-indol-3-yl]-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione (20) as an orange solid; mp >245 °C with dec. MS: (M⁺), m/z 470.

E. 3-(1-Methyl-1H-indol-3-yl)-4-(6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (I-2)

Using the procedure of Example 1, Step F, the N-deprotection reaction of 1.3 g (2.76 mmol) of 3-[1-(2,2-dimethyl-propionyl)-6-nitro-1H-indol-3-yl]-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione. (20) from Step D above with 4.3 ml (6.88 mmol) of a 1.6 molar solution of NaOCH₃ in 65 ml of methanol yielded 300.6 mg (28.1%) of 3-(1-methyl-1H-indol-3-yl)-4-(6-nitro-1H-indol-3-yl)-pyrrole-2,5-dione (I-2) as a red solid after crystallization from ethyl acetate and hexane; mp >260 °C. MS: (M⁺), m/z 386.

EXAMPLE 4

TABLET FORMULATION

Item	Ingredients	mg/Tablet					
		5	25	100	250	500	750
1	Compound A*	5	25	100	250	500	750
2	Anhydrous Lactose	103	83	35	19	38	57
3	Croscarmellose Sodium	6	6	8	16	32	48
4	Povidone K30	5	5	6	12	24	36
5	Magnesium Stearate	1	1	1	3	6	9
	Total Weight	120	120	150	300	600	900

*Compound A represents a compound of the invention.

Manufacturing Procedure:

1. Mix Items 1, 2 and 3 in a suitable mixer for 15 minutes.
2. Granulate the powder mix from Step 1 with 20% Povidone K30 Solution (Item 4).
- 5 3. Dry the granulation from Step 2 at 50°C.
4. Pass the granulation from Step 3 through a suitable milling equipment.
5. Add the Item 5 to the milled granulation Step 4 and mix for 3 minutes.
6. Compress the granulation from Step 5 on a suitable press.

10

EXAMPLE 5**CAPSULE FORMULATION**

Item	Ingredients	mg/Tablet				
1	Compound A *	5	25	100	250	500
2	Hydrous Lactose	159	123	148	--	--
3	Corn Starch	25	35	40	35	70
4	Talc	10	15	10	12	24
5	Magnesium Stearate	1	2	2	3	6
	Total Fill Weight	200	200	300	300	600

15

* Compound A represents a compound of the invention.

Manufacturing Procedure:

1. Mix Items 1, 2 and 3 in a suitable mixer for 15 minutes.
- 20 2. Add Items 4 & 5 and mix for 3 minutes.
3. Fill into a suitable capsule.

EXAMPLE 6**INJECTION SOLUTION/EMULSION PREPARATION**

Item	Ingredient	mg/ml
1	Compound A *	1 mg
2	PEG 400	10-50 mg
3	Lecithin	20-50 mg
4	Soy Oil	1-5 mg
5	Glycerol	8-12 mg
6	Water q.s.	1 ml

5 * Compound A represents a compound of the invention.

Manufacturing Procedure:

1. Dissolve item 1 in item 2
- 10 2. Add items 3, 4 and 5 to item 6 and mix until dispersed, then homogenize.
3. Add the solution from step 1 to the mixture from step 2 and homogenize until the dispersion is translucent.
4. Sterile filter through a 0.2 μ m filter and fill into vials.

15

EXAMPLE 7**INJECTION SOLUTION/EMULSION PREPARATION**

Item	Ingredient	mg/ml
1	Compound A *	1 mg
2	Glycofurol	10-50 mg
3	Lecithin	20-50 mg
4	Soy Oil	1-5 mg
5	Glycerol	8-12 mg
6	Water	q.s. 1 ml

20 * Compound A represents a compound of the invention.


25

Manufacturing Procedure:

- 5 1. Dissolve item 1 in item 2
2. Add items 3, 4 and 5 to item 6 and mix until dispersed, then homogenize.
3. Add the solution from step 1 to the mixture from step 2 and homogenize until the dispersion is translucent.
4. Sterile filter through a 0.2 μm filter and fill into vials.

CLAIMS

1. A compound of formula




5

wherein R^1 is hydrogen and R^2 is methyl or
 R^1 is methyl and R^2 is hydrogen or
 R^1 is hydroxymethyl and R^2 is methyl

as well as pharmaceutically acceptable prodrugs or pharmaceutically acceptable salts thereof.

10


2. A compound of claim 1 of the formula



15


and pharmaceutically acceptable prodrugs or pharmaceutically acceptable salts of said compound.

3. A compound of the formula



- 5 and pharmaceutically acceptable prodrugs or pharmaceutically acceptable salts of said compound.

4. A compound of the formula



10

and pharmaceutically acceptable prodrugs or pharmaceutically acceptable salts of said compound.

15

INTERNATIONAL SEARCH REPORT

Interr. nal Application No
PCT/EP 99/01534

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D403/14 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 328 026 A (F. HOFFMANN-LA ROCHE & CO.) 16 August 1989 cited in the application * page 18, line 28; page 3, line 7-12; claim 1 *	1,5
Y	WO 98 04551 A (F. HOFFMANN-LA ROCHE AG) 5 February 1998 * page 15-16: table; page 2, line 7-10 *	1,5-7
Y	WO 98 04552 A (F. HOFFMANN-LA ROCHE AG) 5 February 1998 * page 2, line 7-10; claim 1 *	1,5-7
A	WO 98 04553 A (F. HOFFMANN-LA ROCHE AG) 5 February 1998 see page 1	1,5-7
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

1 July 1999

Date of mailing of the international search report

09/07/1999


Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van Bijlen, H

5. A pharmaceutical composition comprising a compound of formula



wherein R¹ is hydrogen and R² is methyl or
 R¹ is methyl and R² is hydrogen or
 R¹ is hydroxymethyl and R² is methyl

or a pharmaceutically acceptable salt or prodrug of said compound and a pharmaceutically acceptable carrier.

6. A compound according to any one of claims 1-4 for use as an antitumor drug.
7. The use of a compound claimed in any one of claim 1-4 for the treatment of solid tumors or the preparation of pharmaceutical compositions.
8. The compounds, compositions, processes and uses as hereinbefore described.

*

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/01534

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 328026	A	16-08-1989	AT 88704 T	15-05-1993
			AU 2965889 A	10-08-1989
			CA 1320194 A	13-07-1993
			CZ 8900752 A	13-12-1995
			DK 55889 A	11-08-1989
			ES 2054890 T	16-08-1994
			FI 890652 A,B,	11-08-1989
			IE 63489 B	03-05-1995
			IL 89167 A	27-02-1994
			JP 1233281 A	19-09-1989
			JP 1994298 C	22-11-1995
			JP 7030071 B	05-04-1995
			MX 14871 A	01-09-1993
			PH 25185 A	27-03-1991
			PT 89661 A,B	04-10-1989
			SK 75289 A	06-05-1998
			SU 1799382 A	28-02-1993
			US 5057614 A	15-10-1991
			YU 28489 A	30-06-1991
WO 9804551	A	05-02-1998	AU 4296397 A	20-02-1998
			EP 0915870 A	19-05-1999
			HR 970415 A	31-08-1998
WO 9804552	A	05-02-1998	AU 3769097 A	20-02-1998
			EP 0915872 A	19-05-1999
			HR 970414 A	30-06-1998
WO 9804553	A	05-02-1998	AU 4296497 A	20-02-1998
			EP 0915871 A	19-05-1999
			HR 970417 A	31-08-1998

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/01534

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>PETER D. DAVIS ET AL.: "Inhibitors of Protein Kinase C. 1. 2,3-Bisarylmalimides" JOURNAL OF MEDICINAL CHEMISTRY., vol. 35, no. 1, - 1992 pages 177-184, XP002045287 WASHINGTON US</p> <p>* table IV, compound no 44; page 177-181 *</p> <p>-----</p>	1,5